
Longeveron (LGVN) Stock Forecast & Price Target
Longeveron (LGVN) Analyst Ratings
Bulls say
Longeveron Inc. is poised for significant growth due to its innovative stem cell therapy, Lomecel-B, which has demonstrated remarkable safety and efficacy in clinical trials, particularly in delivering 100% five-year transplant-free survival in Hypoplastic Left Heart Syndrome patients. The company's promising pipeline includes indications for Alzheimer's disease and aging-related frailty, reflecting its commitment to addressing critical unmet medical needs in aging-related health challenges. A revised discounted cash flow analysis suggests a substantial upside potential in the stock price, indicating strong market confidence in the company’s future success and potential FDA approvals.
Bears say
Longeveron Inc. has experienced a significant decline of approximately 56% year-to-date, primarily attributed to concerns surrounding the safety profile of Lomecel-B in clinical trials, particularly for Hypoplastic Left Heart Syndrome patients. Additionally, the ongoing ELPIS II study may fail to demonstrate positive efficacy, which could further hinder the company’s progression in the competitive biotech landscape. The potential for delays in securing necessary funding, regulatory approval, and achieving effective market penetration adds another layer of financial uncertainty that negatively impacts investor confidence.
This aggregate rating is based on analysts' research of Longeveron and is not a guaranteed prediction by Public.com or investment advice.
Longeveron (LGVN) Analyst Forecast & Price Prediction
Start investing in Longeveron (LGVN)
Order type
Buy in
Order amount
Est. shares
0 shares